News | October 15, 2014

AtriCure Completes Enrollment in Post Approval Study for the Synergy Ablation System

Study looks to evaluate effectiveness of surgical ablation procedure for AFib patients

October 15, 2014 — AtriCure, Inc. today announced enrollment in the ABLATE Post Approval Study (PAS) is complete.

As of Oct. 3, 2014, the ABLATE PAS enrolled 365 patients at 40 hospitals across the United States. AtriCure expects to release preliminary data from the study in about a year, with a complete report expected to be published in three years.

The ABLATE PAS evaluates clinical outcomes in patients with non-paroxysmal (persistent or longstanding persistent) forms of atrial fibrillation (AFib) who were treated utilizing the AtriCure Synergy Ablation System to perform the Maze IV procedure. The non-paroxysmal Afib patient group represents about half of the diagnosed patient population and who are extremely challenging to manage with conventional medical therapy or catheter ablation.

“The PAS study is intended to build additional evidence of the safety, efficacy and long-term durability of the Maze IV concomitant treatment for Afib using AtriCure’s proprietary surgical devices,” said Patrick McCarthy, M.D., director of the Bluhm Cardiovascular Institute at Northwestern University Feinberg School of Medicine and lead physician for the ABLATE PAS.

The AtriCure Synergy Ablation System is the first and only medical device to receive Food and Drug Administration (FDA) approval for the treatment of Afib in patients with persistent and long-standing persistent Afib undergoing coronary artery bypass grafting and/or valve replacement or repair.

The initial ABLATE study was completed prior to AtriCure receiving a premarket approval (PMA) for the Synergy Ablation System. This study reported results that showed 84 percent of patients free from Afib at six months following an open concomitant Maze IV treatment, and 75 percent of patients free from Afib and off of anti-arrhythmic pharmaceuticals at a mean follow-up of 22 months when assessed by 48-hour Holter monitors. The intent of the ABLATE PAS study is to demonstrate the positive results from the Maze IV treatment used in the original ABLATE study is reproducible and reliable when performed at hospitals across the country.

More than 2.7 million Americans are living with Afib, a cardiac rhythm disorder that increases in prevalence with age. Afib is responsible for nearly 100,000 deaths and adds $26 billion in expenses to the United States healthcare system each year. Afib is associated with a five-fold increased risk of stroke.

For more information: www.atricure.com

 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init